Integra LifeSciences (IART) Tops Q4 EPS by 1c, Revenues Miss; Offers FY20 EPS Mid-Point Guidance Above Consensus, FY20 Revenue Outlook Below Consensus
Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.68, $0.01 better than the analyst estimate of $0.67. Revenue for the quarter came in at $395.1 million versus the consensus estimate of $397.5 million.
Fourth Quarter 2019
- Reported revenue increased 3.1% to $395.1 million and organic sales increased 4.6% over the fourth quarter 2018.
- GAAP earnings per diluted share were $0.18, compared to $0.29 in the fourth quarter 2018.
- Adjusted earnings per diluted share were $0.68, compared to $0.65 in the fourth quarter of 2018.
GUIDANCE:
Integra LifeSciences sees FY2020 EPS of $3.00-$3.05, versus the consensus of $3.00. Integra LifeSciences sees FY2020 revenue of $1.55-1.57 billion, versus the consensus of $1.59 billion.
For earnings history and earnings-related data on Integra LifeSciences (IART) click here.